axicabtagene ciloleucel (Yescarta) Report issue

Cell therapy Orphan Drug FDA Approved FDA Breakthrough Therapy FDA

Active Ingredient History

NOW
  • Now
Axicabtagene ciloleucel, sold under the brand name Yescarta, is a treatment for large B-cell lymphoma that has failed conventional treatment. T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor. The resulting chimeric antigen receptor T cells (CAR-Ts) that react to the cancer are then given back to the person to populate the bone marrow. Axicabtagene treatment carries a risk for cytokine release syndrome (CRS) and neurological toxicities.   Wikipedia

More Chemistry

Drug Pricing (per unit)

United States

$284904.5200 - $373000.0000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

axicabtagene ciloleucel

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue